Trial Profile
Failure patterns to crizotinib and survival benefit in advanced ALK-positive lung adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 25 Sep 2015 New trial record